Mason M, Currey H L, Barnes C G, Dunne J F, Hazleman B L, Strickland I D
Br Med J. 1969 Feb 15;1(5641):420-2. doi: 10.1136/bmj.1.5641.420.
The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects. This form of therapy promises to be an advance in the management of severe rheumatoid arthritis.
在双盲条件下,对硫唑嘌呤降低重症类风湿性关节炎患者皮质类固醇需求量的能力进行了与安慰剂对照的测试。12个月后,平均剂量显著降低了36%,且没有出现不当的副作用。这种治疗方式有望成为重症类风湿性关节炎治疗的一项进展。